«It is our responsibility to strengthen business interaction with research institutes,» said Kira Zaslavskaya at the Kommersant Publishing House conference

Kira Zaslavskaya, Director for New Products at Promomed Group, spoke about the solutions that will help maintain the innovativeness of domestic pharmaceuticals in modern realities in her presentation at the «Pharma-2022: launching the strategy for the development of pharmaceutical industry for the period until 2030» conference.

«As a full-cycle manufacturer with our own R&D resources, we consider it socially responsible and important to interact with research institutes. In particular, Promomed has become an industrial partner for a number of fundamental research projects at the Sirius University, Mordovia State University, the Endocrinology Research Center and others. We believe that this practice should be continued.

Interdisciplinary conferences are now becoming a particularly important format that allows you to bring together not only doctors and representatives of research institutes, but also participants in the pharmaceutical industry, which in turn will accelerate the introduction of innovations, expand dialogue, and create a single information space.

The implementation of the idea to form a common platform for the inventory of R&D and create a common drug search system, formulated in the Pharma-2030 program, will not only rationalize the search for new molecules, but will certainly serve as cooperation between pharmaceutical manufacturers,» Kira Zaslavskaya illustrated her speach with these steps among others.

At the «Pharma-2022: launching the strategy for the development of pharmaceutical industry for the period until 2030» conference organized by the Kommersant Publishing House, representatives of the pharmaceutical industry discussed the necessary steps and risks for the development of the industry and the drug market in the current conditions of sanctions pressure from foreign states.